34
- Boku N, Yamamoto S, Fukuda H et al (2009)
Fluorouracil versus combination of irinotecan
plus cisplatin versus S-1 in metastatic gastric
cancer: a randomised phase 3 study. Lancet
Oncol 10:1063–1069 - Koizumi W, Narahara H, Hara T et al (2008)
S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS
trial): a phase III trial. Lancet Oncol
9:215–221 - Ajani JA, Rodriguez W, Bodoky G et al (2010)
Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluoro-
uracil in advanced gastric or gastroesophageal
adenocarcinoma study: the FLAGS trial. J Clin
Oncol 28:1547–1553 - He MM, Wu WJ, Wang F et al (2013) S-1-
based chemotherapy versus capecitabine- based
chemotherapy as first-line treatment for
advanced gastric carcinoma: a meta-analysis.
PLoS One 8:e82798 - Kobayashi M, Tsuburaya A, Nishikawa K et al
(2015) A randomized phase II trial of
capecitabine plus cisplatin (XP) versus S-1 plus
cisplatin (SP) as a first-line treatment for
advanced gastric cancer: XP ascertainment ver-
sus SP randomized PII trial (XParTS II). J Clin
Oncol 33(Suppl 3; abstr 105) - Al-Batran SE, Hartmann JT, Probst S et al (2008)
Phase III trial in metastatic gastroesophageal ade-
nocarcinoma with fluorouracil, leucovorin plus
either oxaliplatin or cisplatin: a study of the
Arbeitsgemeinschaft Internistische Onkologie.
J Clin Oncol 26:1435–1442 - Yamada Y, Higuchi K, Nishikawa K et al (2015)
Phase III study comparing oxaliplatin plus S-1
with cisplatin plus S-1 in chemotherapy-naïve
patients with advanced gastric cancer. Ann
Oncol 26:141–148 - Van Cutsem E, Moiseyenko VM, Tjulandin S
et al (2006) Phase III study of docetaxel and
cisplatin plus fluorouracil compared with cis-
platin and fluorouracil as first-line therapy
for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol 24:
4991–4997 - Al-Batran SE, Hartmann JT, Hofheinz R et al
(2008) Biweekly fluorouracil, leucovorin,
oxaliplatin, and docetaxel (FLOT) for patients
with metastatic adenocarcinoma of the stom-
ach or esophagogastric junction: a phase II trial
of the Arbeitsgemeinschaft Internistische
Onkologie. Ann Oncol 19:1882–1887 - Overman MJ, Kazmi SM, Jhamb J et al (2010)
Weekly docetaxel, cisplatin, and 5-fluorouracil
as initial therapy for patients with advanced
gastric and esophageal cancer. Cancer
116:1446–1453
43. Tebbutt NC, Cummins MM, Sourjina T,
Strickland A, Van Hazel G, Ganju V, Gibbs D,
Stockler M, Gebski V, Zalcberg J, Australasian
Gastro-Intestinal Trials Group (2010)
Randomised, non-comparative phase II study
of weekly docetaxel with cisplatin and
5- fluorouracil or with capecitabine in oesopha-
gogastric cancer: the AGITG ATTAX trial. Br
J Cancer 102:475–481
44. Koizumi W, Kim YH, Fujii M et al (2014)
Addition of docetaxel to S-1 without platinum
prolongs survival of patients with advanced
gastric cancer: a randomized study (START).
J Cancer Res Clin Oncol 140:319–328
45. Dank M, Zaluski J, Barone C et al (2008)
Randomized phase III study comparing iri-
notecan combined with 5-fluorouracil and
folinic acid to cisplatin combined with 5-flu-
orouracil in chemotherapy naive patients
with advanced adenocarcinoma of the stom-
ach or esophagogastric junction. Ann Oncol
19:1450–1457
46. Guimbaud R, Louvet C, Ries P et al (2014)
Prospective, randomized, multicenter, phase
III study of fluorouracil, leucovorin, and irino-
tecan versus epirubicin, cisplatin, and
capecitabine in advanced gastric adenocarci-
noma: a French intergroup (Fédération
Francophone de Cancérologie Digestive,
Fédération Nationale des Centres de Lutte
Contre le Cancer, and Groupe Coopérateur
Multidisciplinaire en Oncologie) study. J Clin
Oncol 32:3520–3526
47. Thuss-Patience PC, Kretzschmar A, Bichev D
et al (2011) Survival advantage for irinotecan
versus best supportive care as second-line che-
motherapy in gastric cancer—a randomised
phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer
47:2306–2314
48. Ford HE, Marshall A, Bridgewater JA (2014)
Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma
(COUGAR-02): an open-label, phase 3 ran-
domised controlled trial. Lancet Oncol
15:78–86
49. Janowitz T, Thuss-Patience P, Marshall A et al
(2016) Chemotherapy vs. supportive care
alone for relapsed gastric, gastroesophageal
junction, and oesophageal adenocarcinoma: a
meta-analysis of patient-level data. Br J Cancer
114:381–387
50. Kang JH, Lee SI, Lim DH et al (2012) Salvage
chemotherapy for pretreated gastric cancer: a
randomized phase III trial comparing chemo-
therapy plus best supportive care with best
supportive care alone. J Clin Oncol 30:
1513–1518
Ka-On Lam and Dora L. W. Kwong